Daronrix

Complete virus flu vaccine of a pandemic virus strain inactivated which contains an antigen in accordance with:
A/Vietnam/1194/2004 (H5N1)*** 15 microgram**
per vaccine dose (0.5 ml)

* bred in eggs
** Haemaglutinin
*** adjuvanted on aluminum phosphate 0.45 milligram Al3+ and hydratisized an aluminum hydroxide 0.05 milligram Al3+

Other components
Sodium chloride, sodium mono hydrogen phosphate-dodecahydrate, potassium dihydrogen phosphate, potassium chloride, magnesium chloride-hexahydrate, thimerosal (50microgramm), water for injection purposes.

A H5N1 virus strain was initially used for the approval. The official data for the current production have not been presented to us yet. Presumably it is the virus strain:

A/California/7/2009 (H1N1) ‐like virus

Daronrix side effects

Side effects that were observed in the course of clinical trials with various formulations (H5N1, H2N2 and H9N2)
(N=941) of the model vaccine:

Very frequent (≥1/10),
Frequent (≥1/100 bis <1/10), 
Occasional(≥1/1.000 bis <1/100), 
Rare (≥1/10.000 bis <1/1.000), 
Very rare (<1/10.000),
Not known (cannot be estimated on the basis of available data).

Infections and parasite diseases

Occasional: Nasopharyngitis, rhinitis

Diseases of the nervous system

Very frequent: headache

Diseases of the skin and subcutaneous tissue

Frequent: profuse sweating, bleeding of the skin

Skeleton muscles, diseases of tissue and bones

Frequent:  Myalgia,  arthralgia

General diseases and afflictions at the site of injection

Very frequent: Pain and redness at the injection site, fatigue.

Frequent: Swelling and hardening at the injection site, chills, fever
Occasional: Itchiness at the injection site

During the post marketing observation of interpandemic (seasonal), trivalent vaccines the following side effects were reported:
Occasional (≥1/1.000 to <1/100):
General skin reactions, including pruritis, urticaria or non-specific rashes.